Human trial
Larazotide primary study · PMID 25683116
342 adults with celiac disease and persistent symptoms while maintaining a gluten-free diet.
Reported findings. The 0.5-mg experimental arm improved the primary Celiac Disease Gastrointestinal Symptom Rating Scale score versus placebo (modified intention-to-treat n=340; ANCOVA P=.022, repeated-measures P=.005). Participants maintained a gluten-free diet.
Nonresponse. The 1- and 2-mg experimental arms did not differ from placebo on any endpoint. Mixed trial-arm outcomes do not establish prescribing guidance.
Harms. Safety was comparable with placebo in this trial; this does not establish long-term safety or commercial-preparation equivalence.
Limits. Mixed dose-ranging results. This is not permission to consume gluten, proof of general leaky-gut treatment, or evidence for an acetylated commercial blend.
Preparation: Experimental larazotide acetate; commercial or acetylated-blend equivalence unverified. Route: Unknown in reviewed excerpt; do not infer.
Read original source ↗Editorial review 2026-10-09. Clinician review pending.